Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations & Sustainability

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Q1/21 Results

Fresenius with good start to 2021 despite ongoing COVID-19 impact

Presentation (PDF)

Highlights

LATEST

May 06, 2021 - 01:30 PM | Bad Homburg, Germany

Conference Call Q1 2021, Fresenius

Live Webcast

Webcast Import (ICS) Investor News (PDF) Presentation (PDF) Transcript (PDF)

LATEST

Financial Highlights Q1/21

Sales

€ 8984 m

+3%¹

Q1/20: €9,135 m

Dividend²

€ 0.88

+5%

FY/19: €0.84

EBIT³

€ 1006 m

-6%¹

Q1/20: €1,125 m

Employees

310,842

Dec. 31, 2020: 311,269

Net Income^{3, 4}

€ 435 m

-2%¹

Q1/20: €465 m

Earnings per Share^{3, 4}

€ 0.78

-2%¹

FY/20: €0.83

¹ In constant currency
² Proposal

³ Before special items
⁴ Net income attributable to shareholders of Fresenius SE & Co. KGaA

CEO message

“In view of the adversity and uncertainties that COVID-19 continues to bring, we are satisfied with our start in 2021. (…) That makes me optimistic that we can reach our targets. (…) At the same time, we are moving ahead with our planning for cost and efficiency measures. These measures will create a strong foundation for accelerated and sustainable growth against the backdrop of long-term growth trends supporting our core businesses. Growth that contributes to ever better medicine for ever more people.”

Stephan Sturm, Chairman of the Management Board

Investor News (PDF) More information

Business Segments
- Organic treatment growth impacted by COVID-19 pandemic as expected
- Reported revenue and earnings continued to be adversely affected by exchange rate effects
- Earnings development supported by phasing and expected lower SG&A expense anticipated to reverse throughout the year
- Financial targets for FY 2021 confirmed
Read more (PDF)
Business Segments
- North America performance impacted by COVID-19 and temporary manufacturing issues
- Solid performance in Europe masked by prior-year COVID-19 related demand spike
- Emerging Markets showed strong sales and earnings growth; China with excellent performance given dynamic recovery of elective treatment activity
Read more (PDF)
Business Segments
- Helios Spain delivers significant organic sales and earnings growth given recovery of treatment activity
- Helios Germany continues to be compensated by government for foregone elective treatments
- Growth additionally fueled by contributions from acquisitions in Germany and Latin America
Read more (PDF)
Business Segments
- Continued significant negative COVID-19 impact
- Project business marked by COVID-19 related delays, cancellations and global supply chain restraints
- Rehabilitation business remains impacted by fewer elective surgeries
- Technical high-end service business remains robust
Read more (PDF)

Annual Report 2020
- The Fresenius Annual Report 2020 is now available as an online version with enhanced functionality and as a full-content PDF.
- In addition, we introduce our first our first online Sustainability Report, where you will find detailed information on the topic of sustainability at Fresenius.
- Detailed information on the impact of the pandemic on the Fresenius Group can be found in our online Annual Report.
Annual Report (PDF) Online Annual Report
Non-financial and Sustainability Reporting
We are committed to responsible and sustainable management as part of our corporate culture and day-to-day business practice. Only by doing so can we be perceived as a trustworthy and reliable partner in the health care sector.

Read more
Focus COVID-19
The importance of modern and functional health care for society became particularly clear in 2020 as a result of the COVID-19 pandemic.
Our employees worldwide have tirelessly helped to keep the clinics, dialysis centers, factories and logistics running.

Read more

News

Fresenius with good start to 2021 despite ongoing COVID-19 impact

Guidance for 2021 confirmed - Fresenius Medical Care delivers solid first quarter - Fresenius Kabi shows strong performance in Emerging Markets whilst headwinds continue to impact North American business - Helios Germany continues to be compensated by government for foregone elective treatments; Helios Spain delivers ...
May 06, 2021Fresenius
Fresenius successfully places bonds with a volume of 1.5 billion euros

March 23, 2021Fresenius

Michael Sen to succeed Mats Henriksson as CEO of Fresenius Kabi

March 16, 2021Fresenius Kabi
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Foscarnet Sodium Injection is now available in the United States, expanding the company’s anti-viral portfolio. The drug is used in the treatment of conditions associated with immunocompromised patients.

March 15, 2021Fresenius Kabi

Fresenius achieves 2020 targets and expects healthy business development in 2021 despite ongoing COVID-19 impact

February 23, 2021Fresenius
Fresenius achieves FY/20 guidance demonstrating resilience amid the COVID-19 pandemic – Targets healthy sales growth and at least broadly stable net income year over year in FY/21

February 01, 2021Fresenius

Fresenius Helios acquires fertility services provider Eugin Group

December 21, 2020Fresenius Helios
Brief News
Fresenius improves in climate ranking

Fresenius has once again improved in this year's CDP ranking (formerly "Carbon Disclosure Project"). With a ranking in the second highest category B, Fresenius is one of the leading companies in the health care sector, both in Europe and globally. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 515 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

December 11, 2020Fresenius

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Acetaminophen injection is now available in the United States in ready-to-administer freeflex^® bags, expanding the company’s anesthesia and analgesia portfolio. The drug is used in the hospital setting for pain management and fever reduction.

December 10, 2020Fresenius Kabi
Brief News
Fresenius Kabi launches its first specialty IV drug in the U.S.

Icatibant injection, an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema in adults, expands the company’s generic drug portfolio. Icatibant Injection is supplied as a prefilled, single-use syringe that is self-administered subcutaneously at the patient’s home or doctor’s office. In conjunction with launching its first specialty IV drug in the U.S., Fresenius Kabi is also launching KabiCare in the U.S., a comprehensive patient support program with case managers, co-pay assistance programs, injection training, and a patient assistance program.

December 01, 2020Fresenius Kabi

Brief News
Fresenius Helios reporting figures on intensive care occupancy

Fresenius Helios has started publishing daily figures on the occupancy rate for intensive care beds in its 86 German hospitals. The website of each hospital will report the number of COVID-19 patients in the hospital’s regular and intensive care wards. It will also publish figures from the Robert Koch Institute, Germany’s national health agency, on the number of new infections in the surrounding region. Helios’ goal is to increase transparency and facilitate a data-based assessment of the pandemic at the local level. Helios Germany currently has a total of 1,300 intensive care beds across the country and could add an additional 1,000 on short notice, in the event of a sharp increase in COVID-19 hospitalizations.

November 02, 2020Fresenius Helios
Fresenius continues to demonstrate resilience amid the COVID-19 pandemic: FY/20 guidance confirmed given accelerated earnings growth in Q3

October 29, 2020Fresenius

Fresenius announces changes to Supervisory Board

October 13, 2020Fresenius
Brief News
Fresenius Helios expands reporting on quality standards

As part of its reporting on quality standards, Fresenius Helios is publishing data on the length of patient stays, patient security and antibiotic use in the company’s German hospitals for the first time. Data from every Helios hospital is compiled in a total of 46 quality categories, including the frequency of surgical interventions and their results, and then published annually. The comparing of different hospitals’ statistics through the Quality Medicine Initiative yields specific, concrete improvements that can be implemented in day-to-day hospital operations. The initiative, which was jointly founded by Fresenius Helios, now includes more than 400 hospitals in Germany and Switzerland.

October 09, 2020Fresenius Helios

Brief News
Fresenius Kabi launches its first RFID smart-labeled product in the U.S.

Diprivan® (Propofol) injection, an anesthetic, is the company’s first smart-labeled product with radio frequency identification (RFID) technology and the 20 mL vial is now available in this enhanced presentation in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. Fresenius Kabi expects to introduce numerous other products with RFID technology in the coming year.

October 08, 2020Fresenius Kabi
Brief News
Fresenius Helios enters healthcare agreement with hotel operator in Spain

Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has signed an agreement with Vincci Hotels to offer health careto guests in all accommodations in Spain. The service includes 24/7 medical assistance, either by video call, in person or by a doctor’s visit in the hotel, if necessary. This service is offered in several languages to meet the demands from international guests.

October 07, 2020Fresenius Helios

Fresenius successfully places bonds with a volume of one billion euros

September 21, 2020Fresenius
Brief News
2021 DRG inflator for German hospitals set at 2.53%

The price increase for hospital services in Germany has been set at 2.53% for 2021. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 14, 2020Fresenius Helios

Brief News
Fresenius Helios publishes study on intensive care COVID-19 patients

Fresenius Helios has published initial results from a study of all COVID-19 patients admitted to Helios hospitals in Germany that has been conducted since the start of the pandemic: Two of every three COVID-19 patents in intensive care in Germany require mechanical ventilation. One-third of ventilated intensive care patients die, compared with one-quarter of non-ventilated intensive care patients. This shows that the clinical course of COVID-19 patients in Germany is as poor as in countries hit harder by the pandemic such as Italy, France, the United Kingdom and Belgium. Helios, supported by the Brandenburg Medical School, started in February to collect and analyze data on COVID-19 patents treated in the Helios’ 86 German hospitals. These and additional findings that Helios makes from the study are expected to help in the development of a treatment for the virus.

August 25, 2020Fresenius Helios
Fresenius acquires Malteser hospitals in German state of North Rhine-Westphalia

August 20, 2020Fresenius Helios

Brief News
Fresenius Kabi introduces RFID Smart Labels for Medications in the U.S.

Beginning in Q4 2020, Fresenius Kabi will introduce smartlabels with radio frequency identification (RFID) technology for medications frequently used in the operating room in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. The first products in the smartlabel portfolio are anesthesia and analgesia products in prefilled syringes and vials.

August 18, 2020Fresenius Kabi
Solid H1 results in light of significant contributions to combat COVID-19 – Accelerated earnings growth expected in H2 – New FY/20 guidance incorporates estimated COVID-19 effects

July 30, 2020Fresenius

Brief News
Curalie cooperates with ‘Wir für Gesundheit‘ and Debeka

The Berlin-based digital health company Curalie, a subsidiary of the Fresenius healthcare group, has entered a cooperation agreement with the “Wir für Gesundheit” quality medical care network and the health insurer Debeka. In the first step, a prevention app through which regular medical check-ups can be carried out, along with other functions, will be added to PlusCard. A supplementary company health insurance that companies can offer to their employees, PlusCard was jointly developed by “Wir für Gesundheit” and Debeka and has been offered since 2014. Additional digital components are planned for the prevention app, including a telemedicine function for the care of chronically ill patients.

July 28, 2020Fresenius
Brief News
Fresenius Helios publishes sustainability report

Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals, the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.

July 08, 2020Fresenius Helios

Fresenius holds virtual General Meeting on August 28, 2020 – dividend proposal unchanged

July 08, 2020Fresenius
Brief News
Fresenius Kabi expands pre-filled syringe portfolio in the U.S.

Morphine Sulfate Injection is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes in MicroVault packaging. MicroVault packaging is designed to support the secure dispensing of controlled substances, for example via transparent hard plastic packaging allowing bar code scanning and visual inspection as well as a tamper evident seal.

June 23, 2020Fresenius Kabi

Brief News
Drug from Fresenius Kabi now available in the U.S. after Emergency Use Authorization

Following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization, Fresenius Kabi Propoven 2% is now available in the U.S. Propoven 2% is a higher concentrated dosage form of propofol compared to Fresenius Kabi’s FDA-approved Diprivan® 1%, providing clinicians with another sedation option for ventilated COVID-19 patients. The higher concentration presentation allows Fresenius Kabi to support more patients through more efficient use of existing manufacturing capacity.

June 15, 2020Fresenius Kabi
Fresenius Helios acquires hospital in western Germany

May 29, 2020Fresenius Helios

Brief News
Fresenius Kabi enters marketing agreement for biosimilar product

Fresenius Kabi and the pharmaceutical company medac have agreed to cooperate in Germany in the area of treatments for rheumatic illnesses. On June 1, medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with. This biosimilar, developed by Fresenius Kabi and launched last year in Europe, is used to treat autoimmune illnesses such as arthritis and psoriasis. medac is a leading provider of methotrexate (metex® PEN, metex® FS) for the parenteral treatment of patients with chronic inflammatory diseases. Since affected patients are often treated with a combination of methotrexate and adalimumab, the partnership between Fresenius Kabi and medac will offer patients and doctors new benefits and synergies in therapy offerings as well as consulting.

May 28, 2020Fresenius Kabi
Brief News
Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by FDA

Fresenius Kabi announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company`s Biologics License Application (BLA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is an important achievement in the development of Fresenius Kabi’s biosimilar pipeline in the US. Fresenius Kabi also received acceptance for review of its regulatory submission for its pegfilgrastim biosimilar candidate from the European Medicines Agency this month. (* Neulasta® is a registered trademark of Amgen)

May 27, 2020Fresenius Kabi